Last November, Forbes was first to report that a clinical trial of Vytorin had been delayed an unusual 18 months.

FORBES: Is Merck Flying Blind?

One of the report authors, Dr Robert Clarke, from the Clinical Trial Service Unit at the University of Oxford, said that the findings were "reassuring".

BBC: Folic acid 'cancer risk' fears played down by study